Please assess the completion status of the following clinical trial:

Trial Title: Study of KHK2375 in Subjects With Advanced or Recurrent Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Postmenopausal women aged ≥ 20 and \< 75 years at the time of consent;~* Estrogen receptor positive and/or progesterone receptors positive;~* HER2-negative~* Nonresectable advanced or recurrent breast cancer previously treated with nonsteroidal aromatase inhibitor (AI), and planning to be treated with exemestane~Exclusion Criteria:~* Radiation therapy or immuno therapy within 14 days before the first dose of investigational product;~* Chemotherapy, biological medicines, other pharmacotherapy or major surgery within 21 days before the first dose of the investigational product;~* Prior chemotherapies of ≥ 3 regimens for advanced or recurrent breast cancer;~* Ongoing treatment with other investigational product

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 74 Years
- Healthy Volunteers: f

Study Arms:
- KHK2375 PO and Exemestane PO (Type: EXPERIMENTAL): KHK2375 and Exemestane

Based on this trial design, predict the completion outcome and termination type (if applicable).